Strategic acquisition expands biospecimen portfolio

Europa Biosite has announced the acquisition of AMSBIO, a leading supplier of life science products and services specialising in biospecimens, stem cell research, 3D cell culture, glycobiology, and molecular biology. Based in Oxford, UK, with offices in the USA and the Netherlands, AMSBIO serves researchers across Europe and North America.

This strategic acquisition strengthens Europa Biosite’s position in three key growth areas: biospecimens, stem cell research, and regenerative medicine. It also enhances the company’s footprint in the significant US market.

By combining AMSBIO’s comprehensive biorepository of human and animal biospecimens with Research Donors’ human blood biospecimen services, Europa Biosite significantly expands its biospecimen portfolio, enabling it to meet a wider range of research demands.

Alex Sim, Founder and CEO of AMSBIO said: “We were in dialogue with several potential buyers and selected Europa Biosite due to it being the strongest partner to continue the growth and development of the company I founded 37 years ago. Europa Biosite has proven itself to be a leader within our industry, and we are eager to continue this journey together.”

Sune Schmolker, CEO of Europa Biosite said: “I am immensely proud to lead Europa Biosite in bringing together best-in-class life science companies with our mission to raise the standard of life science distribution. We look forward to welcoming AMSBIO’s colleagues to Europa Biosite and Alex Sim to Europa Biosite’s Group Leadership Team.”

The acquisition marks an important milestone in Europa Biosite’s high growth journey with a five-fold increase in sales over the last 5 years.

The financial terms of the transaction were not disclosed.

More information online